Anti-metastatic effect of curcumin analog pentagamaboronon-0-fructose (PGB-0-F) against 4T1 breast cancer cells

Yogi Ertanto (Biotechnology Program, Graduate School of Universitas Gadjah Mada, Jalan Teknika Utara, Sleman, Yogyakarta 55281, Indonesia Army Medical Center, Jalan Mayjen Soetoyo, Cililitan, Jakarta 13640, Indonesia)
Rohmad Yudi Utomo (Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Jalan Sekip Utara, Yogyakarta 55281, Indonesia)
Riris Istighfari Jenie (Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Jalan Sekip Utara, Yogyakarta 55281, Indonesia Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Jalan Sekip Utara, Yogyakarta )
Ratna Asmah Susidarti (Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Jalan Sekip Utara, Yogyakarta 55281, Indonesia Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Jalan Sekip Utara, Yogyakarta )
Edy Meiyanto (Cancer Chemoprevention Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Jalan Sekip Utara, Yogyakarta 55281, Indonesia Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Gadjah Mada, Jalan Sekip Utara, Yogyakarta )

Indonesian Journal of Biotechnology
Vol 23, No 2 (2018)

Development of a chemotherapeutic agent and boron carrying pharmaceutical based on triple-negative breast cancer is important due to its metastatic progression. Metastases are often more dangerous than the primary tumor and they are responsible for 90% of all cancer deaths. The purpose of this study was to explore the anti-metastatic activities of the PGB-0 complex with fructose (PGB-0-F) against 4T1 breast cancer cells. A scratch wound healing assay was carried out to determine the migration inhibition ability of PGB-0-F, while MMP-9 expression was analysed using gelatin zymography. The testing of anti-migration activity showed that PGB-0-F inhibited in 4T1 cells, whereas the gelatin zymography assay revealed a suppression of MMP-9 expression. PGB-0-F inhibited closure on 4T1 metastatic breast cancer cells line compared with the control. PGB-0-F decreased the MMP-9 expression level compared with the control. Based on these results, PGB-0-F has the potential to be developed as a chemotherapeutic agent, and especially as an anti-metastatic agent.